[김창수의 e뉴스 브리핑] Celltrion corona treatment’Recyrona’, initiated a preliminary review of the product approval of the European Medicines Agency

[FETV=김창수 기자] Celltrion announced on the 25th that the European Medicines Agency launched the’Rolling Review (sequential review)’ of Rekirona, a corona19 antibody treatment, and an official review procedure for product approval in Europe was started. GC Green Cross MS announced on the 25th that it has recently signed an export contract for Corona 19 Rapid Antigen Diagnosis Kit with’MCM EVA SRL’, a Romanian medical device distributor. On the 25th, Daewoong Pharmaceutical, a subsidiary specializing in new drug development, announced that it has attracted 14 billion won worth of Series A investment. In this investment, eight major domestic institutional investors including Kiwoom Investment and E&Venture Partners participated.

◆ Celltrion corona treatment’Recyrona’ begins preliminary review of product approval by the European Medicines Agency

On the 25th, the European Medicines Agency (EMA) launched a’Rolling Review (sequential review)’ of Rekkirona (development name: CT-P59, ingredient name: Regdanbimab), a Corona 19 antibody treatment, and is a product in Europe. It said that a formal review process for approval has been initiated.

EMA’s Rolling Review is a system used by the EMA-affiliated Drug User Advisory Committee (CHMP) to accelerate the evaluation of promising treatments or vaccines in crisis situations such as pandemics. This is a method of receiving data and documents on the efficacy, safety, and quality of drugs in real time before the final approval application and reviewing them quickly.

◆ GC Green Cross MS, Corona 19 antigen diagnostic kit export contract to Romania

GC Green Cross MS is spurring the expansion of the European market for Corona 19 diagnostic kits.

GC Green Cross MS, a diagnostic reagent and medical device specialist, announced on the 25th that it recently signed an export contract for the Corona 19 Rapid Antigen Diagnosis Kit with’MCM EVA SRL’, a Romanian medical device distributor.

The diagnostic kits of 6.1 billion won, the volume confirmed in this contract, are scheduled to be shipped in early March, and in the future,’MCM EVA SRL’ and local private and public projects in Romania will jointly respond to the supply by September 2021. It will be expanded to.

◆ Daewoong Pharmaceutical’s subsidiary’Ienterapeutics’ attracts 14 billion won Series A investment

On the 25th, Daewoong Pharmaceutical’s new drug development subsidiary, Ienterapeutics, announced that it has attracted 14 billion won worth of Series A investment.

In this investment, eight major domestic institutional investors including Kiwoom Investment and E&Venture Partners participated. Daily Partners, Yuanta Investment, Aju IB Investment, Korea Omega Investment Finance, Shinhan Capital, and Time Folio Asset Management were also listed as investors.

Ienterapeutics is a specialized company that develops new drugs based on the ion channel platform that has accumulated 15 years of know-how of Daewoong Pharmaceutical. Currently, it has eight pipelines including Nav1.7 non-narcotic analgesics, hearing loss treatment, and brain disease treatment pipelines. I have.

◆ Sejong Medical’s contribution to localization of laparoscopic surgery equipment…Received the’Health Industry Promotion Agency Award’

Sejong Medical announced on the 25th that it has received the Korea Health Industry Promotion Agency Award at the 42nd regular general meeting’Government and Related Organization Leader Awards’ hosted by the Korea Medical Device Cooperative Association on the 23rd.

This is a consecutive award following the Minister of Health and Welfare Award and the Minister of Health Industry Promotion Award in May 2020, and was honored for contributing to the development of the medical device industry.

Sejong Medical, the first global healthcare company, is a medical device manufacturer for laparoscopic surgery that has successfully localized trocar for laparoscopic surgery. It has established itself as a company.

◆ Novocellbio and TecSalud consortium signed a clinical and technology transfer agreement for COVID-19 treatment

Novocellbio, which develops NK immune cell therapy, announced on the 25th that it has signed a joint clinical and cooperation agreement with Mexico’s TecSalud consortium to export the technology of’NOVO-NK’, a treatment for novel coronavirus infection (Corona 19).

The TecSalud Consortium is a group that operates universities and hospitals in Mexico. With this contract, we will secure exclusive rights to the development, manufacturing, and commercialization of NOVO-NK in Mexico.

With the support of the Mexican government, the TecSalud consortium plans to conduct clinical trials on COVID-19 patients at San José Hospital in Nuevo Leon state and then apply them to treatment.